02211.HK
Universal Health International Group Holding Limited
HKSE · Healthcare · Medical - Pharmaceuticals · CN
HKD 0.45
+2.27%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.2B | 520.7M | 711.5M | 1.1B | 1.3B |
| Cost of Revenue | 1.0B | 446.1M | 605.0M | 909.2M | 1.2B |
| Gross Profit | 194.5M | 74.6M | 106.5M | 179.9M | 222.6M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 224.7M | 81.9M | 136.3M | 205.6M | 303.1M |
| General & Admin Expense | 51.9M | — | 33.9M | 40.6M | 57.9M |
| Selling & Marketing Expense | 105.2M | — | 102.5M | 165.0M | 245.2M |
| Other Expenses | 2.6M | — | (4.3M) | (25.8M) | 9.2M |
| Total Operating Expenses | 227.3M | 81.9M | 132.0M | 179.8M | 312.3M |
| Cost and Expenses | 1.3B | 528.0M | 737.0M | 1.1B | 1.4B |
| Operating Income (EBIT) | (32.8M) | (7.3M) | (25.5M) | 82.0K | (98.4M) |
| Non-Operating | |||||
| Interest Income | 1.1M | 464.3K | 622.9K | 383.0K | 925.0K |
| Interest Expense | 6.7M | 5.9M | 1.2M | 1.4M | 1.3M |
| Net Interest Income | (5.8M) | (5.4M) | (1.1M) | (973.0K) | (345.0K) |
| Other Non-Op Income/Expense | (8.2M) | (9.8M) | 2.6M | (2.9M) | (13.7M) |
| Non-Operating Income (excl Interest) | (6.9M) | — | — | 1.5M | (12.0M) |
| EBT (Pre-Tax Income) | (40.0M) | (17.1M) | (22.9M) | (2.8M) | (112.1M) |
| Income Tax Expense | 6.2M | 3.4M | 2.7M | (3.4M) | (6.0M) |
| Bottom Line | |||||
| Net Income | (46.5M) | (20.5M) | (26.0M) | 413.0K | (105.4M) |
| Earnings from Cont. Ops | (42.3M) | (20.5M) | (25.7M) | 580.0K | (106.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (46.5M) | (20.5M) | (26.0M) | 413.0K | (105.4M) |
| Per Share | |||||
| Basic EPS | (HK$0.40) | (HK$0.15) | (HK$0.32) | HK$0.00 | (HK$0.20) |
| Diluted EPS | (HK$0.40) | (HK$0.15) | (HK$0.32) | HK$0.00 | (HK$0.20) |
| Revenue Per Share | HK$8.71 | HK$3.79 | HK$8.88 | HK$1.63 | HK$2.22 |
| Shares | |||||
| Basic Shares Outstanding | 141.4M | 137.4M | 80.1M | 668.6M | 583.1M |
| Diluted Shares Outstanding | 141.4M | 137.4M | 80.1M | 668.6M | 583.1M |
| Profitability Metrics | |||||
| EBITDA | 1.1M | 6.2M | (11.6M) | 12.6M | (70.2M) |
| D&A | 27.1M | 13.5M | 13.9M | 14.0M | 16.2M |
| EBIT | (25.9M) | (7.3M) | (25.5M) | (1.4M) | (86.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026